Navigation Links
New Survey Highlights the Challenges of People Living with Rare Cancer

The online CURE Rare Cancer Survey, sponsored by Novartis Oncology was conducted independently for CURE magazine among 1,365 of its readers living with cancer to uncover challenges facing patients today and better identify their needs.

East Hanover, NJ (PRWEB) September 17, 2009 -- A new national survey shows that nearly one in three patients with rare cancers - twice the number as those with more common cancers - say they received multiple misdiagnoses when their cancer was first discovered. This delay in receiving a final, correct diagnosis leaves the vast majority of patients with rare cancers (75%) feeling very frustrated1a. The online CURE Rare Cancer Survey, sponsored by Novartis Oncology was conducted independently for CURE magazine among 1,365 of its readers living with cancer to uncover challenges facing patients today and better identify their needs1b.

If you or a loved one are among the nearly 35,000 adults in the US who have a rare cancer2,3, you are familiar with these challenges. Rare cancers are difficult to diagnose because symptoms can be absent, masked or mimic those of more common diseases while overall awareness, research and treatment options typically lag behind those for more common cancers4.

According to the survey results, patients with rare cancers are also more likely than those with more common cancers to say they lack access to credible and reliable information, causing them to feel alone in dealing with their disease1c. In fact, 74% believe they must be their own treatment champions1d. Acting as their own advocates, patients with rare cancers are two times more likely to search for disease information online than those with more common cancers1e.

Online resources are increasingly available for those with rare cancers. Novartis Oncology developed programs to help patients become educated on two rare cancers mentioned by survey respondents - chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST):

  • The CML Alliance ( and GIST Alliance ( programs provide valuable information to people with CML and GIST such as information about the rare cancers, treatment goals, the importance of regular testing and check-ups and patient assistance programs.
  • CML Earth ( and GIST Earth ( are social networking communities designed to help patients feel less alone by providing a portal for them to privately share, support and connect with others like themselves. Patient discussion panels show that networking is important to patients with rare cancers who are looking to connect with people who have had similar experiences5.

"These survey results show that patients with rare cancers have an urgent need for comprehensive, accurate information," said John Hohneker, MD, Senior Vice President, US Clinical Development and Medical Affairs, Novartis Oncology. "Our online resources provide patients with CML and GIST accessible, reliable and multi-dimensional support so they can make informed decisions about their treatment options."

Detailed results from the CURE Rare Cancer Survey were published in CURE's fall 2009 issue available at The magazine and Web site also includes the first-ever Patient's Guide to Rare Cancers, which is designed to address the issues raised in the survey and to help patients communicate more effectively with healthcare providers about their cancers.

"Surrounding patients with many levels of support can help them feel less alone in their disease management," said Debu Tripathy, MD, CURE Editor-in-Chief. "Giving patients with rare cancers a better understanding of their disease can ease their frustration."

The complete CURE Rare Cancer Survey report is available online at:, and

1. CURE Media Group. CURE Rare Cancer Survey Report, May 15, 2009.
   a. Section 1, page 13, table 3
   b. Methodology, page 2, lines 1-6
c. Section 7, page 20 , table 1, line3
d. Section 7, page 20, table 1, line 4
   e. Section 7, page 20, table 1, line 9
2. National Cancer Institute. Common Cancer Types. Accessed August 2009.
3. American Cancer Society: Cancer Facts and Figures 2009. Atlanta, Ga: American Cancer Society, 2009. Available at, Accessed August 2009.
4. National Institutes of Health, Rare Diseases Clinical Research Network Fact Sheet. Accessed August 2009.
5. Panel Intelligence, Discussion Panel Transcript: Journey of Survivorship - Round 2. Prepared for Novartis, October 2007.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. National Survey Reveals Healthcare Providers Technological Readiness to Participate in Electronic Health Records Network
2. Survey Finds Overwhelming Majority of Americans Believe Special Interests Hindering Health Care Reform
3. Survey Finds Employers Plan to Continue or Expand Health & Productivity Programs in Spite of Tough Economy
4. New Survey Results on AD/HD Suggest That Later-Life Diagnosis Leads to Lifetime of Challenges
5. Third National Annual Salary Survey for Medical Interpreters Underway
6. First results from major European patient survey show devastating impact of living with breakthrough cancer pain
7. Closing the Addiction Treatment Gap (CATG) Statement on Annual National Survey on Drug Use and Health Data Released by the Substance Abuse and Mental Health Services Administration (SAMHSA)
8. Clarus Research Group Survey: Top Political Strategists React to Obamas Health Care Speech, Rate Effectiveness
9. Survey Shows At-Risk Men Lacking In Prostate Cancer Knowledge
10. First Results From Major European Patient Survey Show Devastating Impact of Living With Breakthrough Cancer Pain
11. AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... ... has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare ... IT Healthcare was recognized as a finalist in the category of Digital Solutions ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... 01, 2015 , ... PYA’s latest white paper, “ PYA ... main “pain point” for merging or aligning healthcare provider organizations—when mergers and other ... This quick-read guidance suggests that failing to recognize the power of an ...
(Date:12/1/2015)... ... 2015 , ... PartnerTech , a leader in high-tech ... 2008. Gary Bruce, President of PartnerTech North America, currently serves as Director for ... of time in Sweden since joining PartnerTech based in Malmo, Sweden. He has ...
(Date:12/1/2015)... ... December 01, 2015 , ... Nurotron Biotechnology Co., Ltd., maker of ... to date. , The order will be from the China Disabled Persons’ Federation, ... System is an effective solution for children and adults suffering from severe and ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... India , December 1, 2015 ... market research report "Immunotherapy Drugs Market by Type of Drug ... Checkpoint Inhibitors), Epidemiology, Regulatory and Pipeline Analysis - Global Forecast ... is poised to reach USD 73,529.2 Million by 2020 from ... from 2015 to 2020. Browse 37 ...
(Date:12/1/2015)... , 1 de diciembre de 2015 /PRNewswire/ ... para cuchillas de precisión, develó hoy un ... identidad de marca. El nuevo logo destaca ... y la ingeniería de productos con cuchillas ... ...
(Date:12/1/2015)... 2015 During the recent 2015 Transcatheter ... Francisco, CA , Medinol Ltd. continued to ... During a satellite symposium, "The BioNIR eDES: The ... Restenosis", a renowned physician panel discussed the key ... Coronary Stent System and the Medinol eDES Coronary ...
Breaking Medicine Technology: